Clinical trials: vincristine sulfate
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
This is a pilot study utilizing Marqibo® (vincristine sulfate liposome injection) combined with dexamethasone, mitoxantrone and asparaginase (UK ALL R3) for relapsed acute lymphoblastic leukemia (ALL).
- Conditions
- ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
- Trial name
- NCT02879643
- Testing
- Marqibo
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Multiple Myeloma
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
1. Primary Objective To assess the response rate of sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) induction therapy as a first line treatment for the patients with multiple…
- Trial name
- NCT00378755
- Testing
- velcade
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Korean Multiple Myeloma Working Party
Lymphoma
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002676
- Testing
- carmustine, cyclophosphamide, cytarabine
- Where
- 21 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
- Trial name
- NCT01412879
- Testing
- rituximab, bendamustine hydrochloride, cyclophosphamide
- Where
- 204 sites in United States
- Volunteers
- 53 people
- Sponsor
- SWOG Cancer Research Network
Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. These T-cell neoplasms account for approximately 10-15% of all lymphomas.
- Conditions
- Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
- Trial name
- NCT07535762
- Testing
- Aclarubicin, Cyclophosphamide, Vincristine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma
- Trial name
- NCT00354835
- Testing
- Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride
- Where
- 226 sites in United States, Australia and 4 more
- Volunteers
- 481 people
- Sponsor
- Children's Oncology Group
Lymphoma
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392990
- Testing
- Regimen A, Regimen B
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer.
- Trial name
- NCT00028886
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 17 sites in Belgium, Netherlands
- Volunteers
- 450 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
This is a prospective, single-arm, multi-center, phase Ib/II clinical trial to evaluate the safety, tolerability, and efficacy of selinexor in combination with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and…
- Trial name
- NCT05577364
- Testing
- Selinexor, R-CHOP Protocol
- Where
- 2 sites in China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Chidamide, R-CHOP Chemotherapy
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
- Conditions
- Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)
- Trial name
- NCT06891157
- Testing
- Chidamide plus R-CHOP
- Where
- China
- Volunteers
- 148 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and <18 years)…
- Trial name
- NCT05748171
- Testing
- Inotuzumab ozogamicin, ALLR3
- Where
- 65 sites in Austria, Belgium and 13 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Lymphoma, Follicular
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
- Trial name
- GOLSEEK-2 (NCT06425302)
- Testing
- Golcadomide, Rituximab, Cyclophosphamide
- Where
- 56 sites in United States, Australia and 11 more
- Volunteers
- 95 people
- Sponsor
- Celgene
Diffuse Large B Cell Lymphoma
Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma
This is a Phase I/II Trial of Decitabine + R-CHOP in Diffuse Large B-Cell Lymphoma
- Trial name
- DR-CHOP (NCT02951728)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Ruijin Hospital
Neuropathy, Cancer
Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.
The goal of this clinical trial is to assess the efficacy of glutamine in preventing the occurrence of vincristine induced neuropathy and to compare the reduction in rate of any dose reductions and premature chemotherapy…
- Trial name
- NCT07287592
- Testing
- Glutamine (Pharmacological doses)
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Lymphoma
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Many cancer patients are prescribed drugs to which their cancer is already resistant - and thus suffer toxicity with no potential for benefit. Previous attempts to assess chemoresistance or sensitivity in vitro have failed.
- Trial name
- NCT01831505
- Testing
- Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Presage Biosciences
Neuroblastoma
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIGB), may carry radiation directly to tumor cells and not harm normal cells.
- Trial name
- NCT00509353
- Testing
- irinotecan hydrochloride, vincristine sulfate, iobenguane I 131
- Where
- 12 sites in United States
- Volunteers
- 26 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Prognostic Cancer Model
Prognostic Significance of ctDNA in HL
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age <60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse…
- Trial name
- NCT06263530
- Where
- 5 sites in Czechia
- Volunteers
- 500 people
- Sponsor
- Interni hematologicka klinika FNKV
Peripheral T-cell Lymphoma
Treatment of Peripheral T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of GDPT regiment (gemcitabine，cisplatin,Prednisone ,Thalidomide ) for patients with Peripheral T-cell lymphoma.
- Trial name
- NCT01664975
- Testing
- GDPT regimen, CHOP regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Mingzhi Zhang
Neuroblastoma
Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more tumor cells.
- Trial name
- NCT00410631
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 80 sites in Germany, Switzerland
- Volunteers
- 642 people
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Leukemia
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells.
- Trial name
- NCT00002812
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 2,078 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.